Back to top
more

ProPhase Labs (PRPH)

(Delayed Data from NSDQ)

$0.78 USD

0.78
2,579,923

-0.65 (-45.45%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $0.78 0.00 (0.00%) 5:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 23.08% and 1.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 0% and 34.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of 48.48% and 14.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 10.91% and 9.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -16.67% and 3.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?

by Zacks Equity Research

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of 36.36% and 24.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -107.06% and 13.18%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -42.86% and 6.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 130% and 18.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -7.35% and 12.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Catalent (CTLT) Stock Jumps 6.8%: Will It Continue to Soar?

by Zacks Equity Research

Catalent (CTLT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ProPhase Labs, Inc. (PRPH) Soars 7.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

ProPhase Labs, Inc. (PRPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -500% and 6.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Fusion Pharmaceuticals Inc. (FUSN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 3.51% and 16.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for ProPhase Labs (PRPH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to ProPhase Labs (PRPH) stock based on the movements in the options market lately.

ProPhase Labs, Inc. (PRPH) Q3 Earnings Miss Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -60% and 28.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Investors Undervaluing Assertio (ASRT) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Zacks Analyst Blog highlights Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs

by Zacks Equity Research

Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs are part of the Zacks top Analyst Blog .

Tirthankar Chakraborty headshot

5 Big Winners as Dollar Strengthens on Fed Rate Hike

by Tirthankar Chakraborty

A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.

Are Medical Stocks Lagging ProPhase Labs (PRPH) This Year?

by Zacks Equity Research

Here is how ProPhase Labs, Inc. (PRPH) and Concert Pharmaceuticals (CNCE) have performed compared to their sector so far this year.

Tracey Ryniec headshot

5 Cheap Healthcare Stocks in 2022

by Tracey Ryniec

Energy, banks and agriculture have plenty of value stocks this year but what about healthcare?

Here's Why ProPhase Labs, Inc. (PRPH) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does ProPhase Labs, Inc. (PRPH) have what it takes to be a top stock pick for momentum investors? Let's find out.